<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="10669"><DrugName>Civacir</DrugName><DrugNamesKey><Name id="42775650">Civacir</Name><Name id="42775649">HCVIG</Name><Name id="42775651">Nabi-Civacir</Name></DrugNamesKey><DrugSynonyms><Name><Value>H-CIG</Value></Name><Name><Value>HCVIG</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Civacir</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Nabi-Civacir</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>hepatitis C antibodies, Nabi/Kedrion</Value></Name><Name><Value>HCIG</Value></Name><Name><Value>Hepatitis C Immune Globulin</Value></Name><Name><Value>Biotest-HCIG</Value></Name></DrugSynonyms><CompanyOriginator id="1036329">Nabi Biologics</CompanyOriginator><CompaniesSecondary><Company id="1021635">Kedrion SpA</Company><Company id="1034585">Biotest Pharmaceuticals Corp</Company><Company id="1036329">Nabi Biologics</Company></CompaniesSecondary><CrossReferences><SourceEntity id="10669" type="Drug"><TargetEntity id="263633" type="siDrug">Hepatitis C immune globulin (human)</TargetEntity></SourceEntity><SourceEntity id="1021635" type="Company"><TargetEntity id="4296199469" type="organizationId">Kedrion SpA</TargetEntity></SourceEntity><SourceEntity id="1034585" type="Company"><TargetEntity id="4297702288" type="organizationId">Biotest Pharmaceuticals Corp</TargetEntity></SourceEntity><SourceEntity id="1036329" type="Company"><TargetEntity id="4297915967" type="organizationId">Nabi Biologics</TargetEntity></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"></TargetEntity><TargetEntity id="D019698" type="MeSH"></TargetEntity><TargetEntity id="-776640207" type="omicsDisease"></TargetEntity><TargetEntity id="430" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="153">Hepatitis C virus infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="582">Antibody polyclonal</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2018-09-18T09:10:35.000Z</LastModificationDate><ChangeDateLast>2018-09-18T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1034585" linkType="Company"&gt;Biotest Pharmaceuticals&lt;/ulink&gt; (a US subsidiary of &lt;ulink linkID="13737" linkType="Company"&gt;Biotest&lt;/ulink&gt;), following its acquisition of &lt;ulink linkID="1036329" linkType="Company"&gt;Nabi Biologics&lt;/ulink&gt; from &lt;ulink linkID="23133" linkType="Company"&gt;Nabi Biopharmaceuticals&lt;/ulink&gt;, and  &lt;ulink linkID="1021635" linkType="Company"&gt;Kedrion&lt;/ulink&gt;  were developing Civacir (Hepatitis C Immune Globulin; Biotest-HCIG), a plasma-derived preparation of human polyclonal antibodies against HCV, for the potential intravenous treatment and prevention of hepatitis C virus (HCV) infection in liver transplant recipients [&lt;ulink linkID="177280" linkType="reference"&gt;177280&lt;/ulink&gt;], [&lt;ulink linkID="857401" linkType="Reference"&gt;857401&lt;/ulink&gt;], [&lt;ulink linkID="857405" linkType="Reference"&gt;857405&lt;/ulink&gt;], [&lt;ulink linkID="1389408" linkType="Reference"&gt;1389408&lt;/ulink&gt;], [&lt;ulink linkID="1447770" linkType="Reference"&gt;1447770&lt;/ulink&gt;]. In July 2013, it was in phase III trials  [&lt;ulink linkID="1389408" linkType="Reference"&gt;1389408&lt;/ulink&gt;];   in November 2014, phase III clinical data were presented  [&lt;ulink linkID="1615108" linkType="Reference"&gt;1615108&lt;/ulink&gt;], [&lt;ulink linkID="1610338" linkType="Reference"&gt;1610338&lt;/ulink&gt;]; in November 2015, data from the trial were presented [&lt;ulink linkID="1712955" linkType="Reference"&gt;1712955&lt;/ulink&gt;]. In April 2017, the drug was listed as being in phase III development [&lt;ulink linkID="1917981" linkType="Reference"&gt;1917981&lt;/ulink&gt;]. However, in September 2018, the drug was not listed on company website, presumed to be discontinued [&lt;ulink linkID="2073346" linkType="Reference"&gt;2073346&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In February 2006, the FDA granted Fast Track status for HCV re-infection in liver transplant patients [&lt;ulink linkID="648181" linkType="Reference"&gt;648181&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2002, the FDA granted Orphan Drug status to Civacir for the prevention of HCV infection in liver transplant recipients [&lt;ulink linkID="472931" linkType="reference"&gt;472931&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In May 2005, the EU Committee for Orphan Medicinal Products adopted a positive opinion on Orphan Drug designation for Civacir in the prevention of recurrent HCV-induced liver disease in liver transplant recipients [&lt;ulink linkID="602371" linkType="Reference"&gt;602371&lt;/ulink&gt;]; in June 2005, Nabi was granted EU Orphan Drug status for this indication [&lt;ulink linkID="608974" linkType="Reference"&gt;608974&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In March 2013, a multicenter, randomized, prospective, open-label, phase III study (&lt;ulink linkID="114131" linkType="Protocol"&gt;NCT01804829&lt;/ulink&gt;;  988) to evaluate the efficacy, safety and pharmacokinetics of Civacir 10% (iv), in orthotopic liver transplant recipients (expected n = 90) was planned to be initiated in the US in May 2013 and planned to complete in December 2014; in July 2013, the trial was initiated  [&lt;ulink linkID="1389408" linkType="Reference"&gt;1389408&lt;/ulink&gt;]. In August 2013, the first patient was treated with Civacir following treatment with virostatics over several weeks and liver transplantation; at that time, the trial was  also being conducted in Canada [&lt;ulink linkID="1462512" linkType="Reference"&gt;1462512&lt;/ulink&gt;]. 	In November 2014, clinical data were presented at The Liver Meeting 2014 in Boston, MA.								Overall, 92% of Biotest-HCIG-treated patients maintained undetectable HCV RNA compared with 80% of controls. At median 9 weeks follow-up, undetectable HCV RNA was reported in four patients who were on Biotest-HCIG [&lt;ulink linkID="1615108" linkType="Reference"&gt;1615108&lt;/ulink&gt;], [&lt;ulink linkID="1610338" linkType="Reference"&gt;1610338&lt;/ulink&gt;]. In April 2015, further clinical data in 63 patients were presented at the 50th EASL Annual Meeting in Austria, Vienna. At peak, anti-HCV levels were approximately 1.5 to 2-fold higher in Civacir 300 mg/kg group when compared with Civacir 200 mg/kg group. Civacir was well tolerated with no drug-related serious adverse events [&lt;ulink linkID="1650932" linkType="Reference"&gt;1650932&lt;/ulink&gt;]. In August 2015, final data were expected by the end of 2015 [&lt;ulink linkID="1685333" linkType="Reference"&gt;1685333&lt;/ulink&gt;]. In November 2015, an ongoing open-label, randomized phase III data were presented at AASLD's Liver Meeting 2015 in San Francisco, CA. HCV recurrence was prevented by Civacir with one and eight re-infections observed in Civacir 300 mg/kg compared with control arms, respectively. Post-liver transplantation re-infection and post-liver transplantation renal dysfunction &amp;lt; and &amp;gt; 4 weeks post-liver transplantation were the adverse events experienced by 29, 20, and 4 and 43, 25, and 32% of patients in the control, Civacir 200 and 300 mg/kg treatment groups, respectively [&lt;ulink linkID="1712955" linkType="Reference"&gt;1712955&lt;/ulink&gt;]. In June 2016, the trial was completed [&lt;ulink linkID="1389408" linkType="Reference"&gt;1389408&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, development was expected to resume in the second half of 2012, once the drug had been reformulated  [&lt;ulink linkID="1282471" linkType="Reference"&gt;1282471&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In February 2006, Nabi was planning a double-blind, phase II, proof-of-concept trial, which would enroll 100 HCV-positive patients, post-liver transplant, who would receive 100, 200 or 400mg/kg of Civacir, or placebo. The endpoints would include progression of liver fibrosis, liver enzyme levels, safety and tolerance. Recruitment was expected to start in the second half of 2006 and run for 12 months, and  results were expected in the second half of 2008 [&lt;ulink linkID="648181" linkType="Reference"&gt;648181&lt;/ulink&gt;]. In October 2006, the timing was postponed to the fourth quarter of that year [&lt;ulink linkID="734573" linkType="Reference"&gt;734573&lt;/ulink&gt;]. In January 2007, Nabi started the phase II trial. The company expected to complete enrollment in the second half of 2007, and report results in the second half of 2008. The randomized, controlled study would include 30 patients, 20 of whom would be given 400 mg/kg Civacir and 10 of whom would receive standard-of-care. The primary endpoints were progression of liver fibrosis on biopsies and HCV levels in liver and serum. The secondary endpoints included liver enzyme levels, safety and tolerance. If the phase II study yielded positive results,  Nabi and Kedrion would begin a pivotal phase III study in the US and Europe  [&lt;ulink linkID="757999" linkType="Reference"&gt;757999&lt;/ulink&gt;]. By June 2010, the trial (&lt;ulink linkID="9452" linkType="Protocol"&gt;NCT00473824&lt;/ulink&gt;; Nabi-3104) of iv Civacir (5%) had been terminated, following the decision by Biotest to pursue a redesigned study [&lt;ulink linkID="1447742" linkType="Reference"&gt;1447742&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A randomized, controlled phase I/II trial of Civacir, conducted by the NIAID Collaborative Anti-Viral Study Group, at five sites in the US, was initiated in April 2002. The trial was designed to determine the safety and antibody levels of Civacir, as well as its effects on the level of HCV circulating in patients' blood and in transplanted livers, and was to evaluate two dose levels of the drug [&lt;ulink linkID="448263" linkType="reference"&gt;448263&lt;/ulink&gt;]. By December 2002, enrollment into the trial had been completed and the company anticipated reporting data from the studies in 2003 [&lt;ulink linkID="472931" linkType="reference"&gt;472931&lt;/ulink&gt;]. In February 2004, preliminary results from this trial were released. Civacir was well tolerated in both the high and low dose treatment arms and although the study was not powered to pick up significant differences in effect, a trend towards reductions in serum &lt;ulink linkID="18030" linkType="Company"&gt;alanine&lt;/ulink&gt; aminotransferase (ALT) levels was observed [&lt;ulink linkID="524086" linkType="reference"&gt;524086&lt;/ulink&gt;], [&lt;ulink linkID="537184" linkType="reference"&gt;537184&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2002, the company had completed phase I/II trials in low-birth-weight neonates and was planning to move forward with studies in liver transplant adults [&lt;ulink linkID="438121" linkType="reference"&gt;438121&lt;/ulink&gt;], [&lt;ulink linkID="438415" linkType="reference"&gt;438415&lt;/ulink&gt;], [&lt;ulink linkID="439478" linkType="reference"&gt;439478&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2000, Nabi expected to begin a phase I/II trial in liver transplant patients in the first half of 2000 [&lt;ulink linkID="357165" linkType="reference"&gt;357165&lt;/ulink&gt;], [&lt;ulink linkID="400120" linkType="reference"&gt;400120&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2015, preclinical data were presented at the 50th EASL Annual Meeting in Austria, Vienna. Civacir potently and dose-dependently neutralized HCV pseudoparticles expressing E1E2 envelope glycoproteins from escape and non-escape variants [&lt;ulink linkID="1651338" linkType="Reference"&gt;1651338&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Under a CRADA formed between Nabi and the &lt;ulink linkID="26857" linkType="Company"&gt;Centers for Disease Control and Prevention&lt;/ulink&gt;, the efficacy of Civacir for preventing/modifying HCV infection in experimentally infected chimpanzees was to be assessed. In August 1999, encouraging preclinical results from a chimpanzee study resulting from this CRADA for Civacir were reported at the XI International Congress of Virology meeting, Sydney, Australia. The results of the study suggested that multiple infusions of the drug were effective in the early termination of HCV viremia in animals challenged with various doses of HCV [&lt;ulink linkID="338447" linkType="reference"&gt;338447&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In August 2006, Nabi licensed &lt;ulink linkID="26459" linkType="Company"&gt;ProMetic&lt;/ulink&gt;'s hyperimmune immunoglobulin extraction technology to improve yields of Civacir [&lt;ulink linkID="686470" linkType="Reference"&gt;686470&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2006, &lt;ulink linkID="1021635" linkType="Company"&gt;Kedrion&lt;/ulink&gt;  agreed to codevelop Civacir. The companies would jointly develop the drug in the US and Europe [&lt;ulink linkID="676444" linkType="Reference"&gt;676444&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 1994, Nabi had filed an IND for H-CIG, an immunoglobulin against HCV infection in liver transplant patients [&lt;ulink linkID="177280" linkType="reference"&gt;177280&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1034585">Biotest Pharmaceuticals Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-18T00:00:00.000Z</StatusDate><Source id="2073346" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1034585">Biotest Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-18T00:00:00.000Z</StatusDate><Source id="2073346" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1021635">Kedrion SpA</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-12-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1036329">Nabi Biologics</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-08-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1036329">Nabi Biologics</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-01-31T00:00:00.000Z</StatusDate><Source id="438121" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1036329">Nabi Biologics</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-08-11T12:23:14.000Z</StatusDate><Source id="177280" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1036329">Nabi Biologics</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-02-05T00:00:00.000Z</StatusDate><Source id="438415" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1021635">Kedrion SpA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-29T00:00:00.000Z</StatusDate><Source id="676444" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1034585">Biotest Pharmaceuticals Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-08-07T00:00:00.000Z</StatusDate><Source id="1462512" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1034585">Biotest Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-12T00:00:00.000Z</StatusDate><Source id="1389408" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1036329">Nabi Biologics</OwnerCompany><Country id="US">US</Country><Indication id="153">Hepatitis C virus infection</Indication><AwardedIndication>Prevention of hepatitis C virus (HCV) re-infection in liver transplant patients</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-02-01T00:00:00.000Z</MileStoneDate><Source id="648181" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1034585">Biotest Pharmaceuticals Corp</OwnerCompany><Country id="EU">EU</Country><Indication id="153">Hepatitis C virus infection</Indication><AwardedIndication>Prevention of recurrent hepatitis C virus induced liver disease in liver transplant recipients</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-02-29T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1034585">Biotest Pharmaceuticals Corp</OwnerCompany><Country id="EU">EU</Country><Indication id="153">Hepatitis C virus infection</Indication><AwardedIndication>Prevention of recurrent hepatitis C virus induced liver disease in liver transplant recipients</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-08T00:00:00.000Z</MileStoneDate><Source id="608974" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1034585">Biotest Pharmaceuticals Corp</OwnerCompany><Country id="EU">EU</Country><Indication id="153">Hepatitis C virus infection</Indication><AwardedIndication>Prevention of recurrent hepatitis C virus induced liver disease in liver transplant recipients</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-05-12T00:00:00.000Z</MileStoneDate><Source id="602371" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1034585">Biotest Pharmaceuticals Corp</OwnerCompany><Country id="US">US</Country><Indication id="153">Hepatitis C virus infection</Indication><AwardedIndication>Prophylaxis of hepatitis C infection in liver transplant recipients.</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-11-14T00:00:00.000Z</MileStoneDate><Source id="472931" type="PR"></Source></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1389408" linkType="reference" linkID="1389408"&gt;1389408&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1021635">Kedrion SpA</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="13737">Biotest AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23133">Aviragen Therapeutics Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="26459">ProMetic Life Sciences Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="15">Drug - CRADA</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="109014" title="Kedrion to codevelop Nabi's Civacir in US and Europe"></Deal><Deal id="109177" title="Nabi to apply ProMetic's mimetic ligands technology to plasma-derived hyperimmune products"></Deal><Deal id="119108" title="Nabi and the CDC agree to form CRADA for evaluation of Civacir "></Deal><Deal id="174282" title="Kedrion to develop and commercialize Nabi's Civacir for HCV related liver disease in Europe"></Deal></Deals><PatentFamilies><PatentFamily id="3295337" number="WO-2016130122" title="Prevention of hepatitis C virus recurrence using a human hepatits C immunoglobulin preparation"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Grifols SA" id="16581"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>